Omeros Corporation · Seattle, WA United States (NASDAQ: OMER)
| 1420 5th Ave., Ste. 2600 | Phone: 206-676-5000 |
| Seattle, WA | Fax: 206-676-5005 |
| 98101 | |
| United States | 
Map This Company |
Omeros Corporation Rankings
Company Description
Omeros doesn't claim to soothe the soul, but it may be able to tame inflammation caused by surgery. The biopharmaceutical company is developing products based on its PharmacoSurgery platform, a combination of low-dose therapeutic agents applied directly to a surgical site to inhibit inflammation. Lead PharmacoSurgery candidate OMS103HP is in clinical trials for its ability to improve joint function and reduce pain following ACL knee reconstruction surgery and arthroscopic meniscectomy (removal of knee cartilage tears). Other candidates are in clinical development for eye and prostate surgeries. In addition to inflammation, Omeros maintains development programs focused on disorders of the central nervous system.
Omeros Corporation Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: OMER Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 70 |
Executives
22 executives listed for Omeros Corporation's Seattle, WA location.
| President, Chairman and CEO | Gregory Demopulos | |
|---|---|---|
| Director Finance and Controller | David Toll | |
| VP Clinical Development and Chief Medical Officer | J. Steven Whitaker |